The week's most telling funding headline in Europe did not come from a consumer app or a crypto exchange. It came from a Stockholm clinic software company and the investor sitting at the top of its cap table. Tandem Health, which is building what it describes as a complete AI medical assistant for European clinics, has raised €86.49 million (roughly $100 million) in Series B funding, according to EU-Startups. The round was led by the Scaleup Europe Fund, a vehicle managed by EQT, with participation from existing backers Kinnevik, Northzone, Amino Collective and Visionaries. Coming only months after the company's previous announcement in June 2025, the deal is a rare example of a European growth round being anchored not by a US crossover fund but by a European manager deploying capital explicitly designed to keep late-stage companies on the continent. Set alongside a cluster of smaller deals across Brussels, Zurich and Zug, and a sharp wobble in global technology equities reported by Bloomberg Markets, the Tandem round offers a compact picture of where European venture capital stands: increasingly concentrated in a handful of defensible sectors, increasingly reliant on public or quasi-public money at the lead position, and increasingly exposed to a sentiment cycle it does not control. Why this matters for the European ecosystem For a decade, the standard critique of European technology has been that it produces excellent seed-stage companies and then loses them, either to US investors who lead the growth rounds and pull headquarters westwards, or to a slow death by under-capitalisation. The scale-up gap is not a rhetorical device; it is the reason so many European unicorns are eventually domiciled in Delaware. The Scaleup Europe Fund exists because policymakers and institutional investors concluded that this gap would not close on its own. Its appearance as lead investor in a $100 million health software round is therefore a proof point, not just a transaction. If the vehicle can repeatedly write cheques of this size into companies with genuine European customer bases, it changes the calculus for founders deciding whether to court Sand Hill Road. If it cannot, the fund risks becoming a well-intentioned footnote. Tandem's sector choice also matters. Healthcare is one of the few markets where Europe's regulatory density is an asset rather than a liability. Clinical documentation, data residency rules and national health system procurement are barriers that American incumbents find genuinely difficult to cross. A company that can sell an AI assistant into fragmented European clinics, with a Nordic base and a European investor syndicate, has a moat that a general-purpose productivity tool does not. The pattern in the smaller rounds The deals below Tandem in size are, in their own way, more revealing of the market's mood. In Brussels, Chift has raised €10.5 million in a Series A led by BlackFin Capital Partners, a specialist European fintech investor managing more than €4 billion, according to EU-Startups. Chift describes itself as a financial connectivity layer: it helps software vendors connect their products to the accounting, banking and payments tools their users already rely on. This is plumbing, not spectacle. But it is precisely the kind of infrastructure that European fintech has historically lacked, given that the continent's financial software landscape is fragmented along national lines to a degree that has no US equivalent. A vendor selling into Belgium, Germany and Spain faces different accounting packages, different e-invoicing mandates and different banking rails in each. A single integration layer that abstracts that away is a real product, and BlackFin's willingness to lead suggests specialist investors see durable demand. In Zurich, Aeon has closed a Seed extension that takes its total Seed funding above €12 million (about $14 million), building on an €8.2 million raise in June 2025, and has simultaneously acquired Aware Health, a German blood diagnostics platform, EU-Startups reports exclusively. Aeon is developing AI-powered whole-body health check-ups, positioning itself in the preventive care market that has attracted heavy attention in the US. Two things stand out. First, a Seed-stage company making an acquisition is unusual and speaks to a market where smaller health startups are finding it hard to raise independently and are open to being absorbed. Second, the extension itself, rather than a clean Series A, hints at investors preferring to top up existing positions at known terms rather than reprice. Both are symptoms of a market that has capital but is cautious about how it labels and prices that capital. In Zug, Ferm Labs has secured €3 million to scale a bioprocessing platform for clean-label food ingredients. The round was led by CDP Venture Capital through its Green Transition Fund, which is financed under NextGenerationEU, alongside a syndicate including Fund F and Redstone working with Euregio+, according to EU-Startups. Here again, the lead investor is a state-linked vehicle. Italy's CDP is a national promotional institution,